An analysis by the Horizon 2020 ProBIO project has found that under 5% of bio-economy projects funded under the Seventh Framework Programme (FP7) have been introduced to market.
Udo Sievers, from i.con innovation, a partner of the ProBIO project, said: “The low level of exploitable results is a result of how programmes are currently oriented, and the next European Framework Programme needs to be more forward-looking and better include commercialisation if we want to see these impacts.”
The common assumption of the debate hosted by MEP Lieve Wierinck, Shadow Rapporteur on the European Parliament’s mid-term assessment of Horizon 2020, was that while the EU has excellent research, it is not turned into market success because Europe lacks entrepreneurial capacity and there is a ‘knowhow gap’ concerning the needs of commercial exploitation.
However, ProBIO also discovered that there are more complex, structural barriers behind the low commercial performance of European research programmes. These have taken a technology-push approach, thus ignoring market conditions, have not included enough commercially active partners, and have not provided full innovation process support.
For more information, please see the website.